乳腺癌治疗研究进展__培训课件.ppt

* As shown in this slide, the efficacy of bevacizumab-containing therapy is very consistent across the three trials. All PFS data shown in this slide are from the stratified analyses, and data were censored for non-protocol therapy received prior to disease progression. In E2100, AVADO and both cohorts of RIBBON-1, PFS was significantly superior in the bevacizumab-containing arm compared with chemotherapy alone, thus meeting the primary endpoint of each trial.1–4 Median PFS was approximately 9–11 months in all four bevacizumab-containing arms.1–4 These trials were not designed to compare chemotherapy regimens, so no data are available to support the use of one combination partner for bevacizumab over the others. References Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res 2009;69(December 15 Suppl.):495s (Abstract 41). Avastin SmPC 2009. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966–72. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(May 20 suppl.):42s (Abstract 1005). * References Cameron D. Bevacizumab in the first-line treatment of metastatic breast cancer. Eur J Cancer Suppl 2008;6:21–8. Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the f